← Eichor
Study identifier: NCT06347068 Synced from ClinicalTrials.gov · July 28, 2026
● Recruiting

Study of Autologous CAR-T Cells Targeting B7-H3 in TNBC iC9-CAR.B7-H3 T Cells

Condition: Breast Cancer · Relapse · Resistant Cancer  ·  Sponsor: UNC Lineberger Comprehensive Cancer Center

PhasePhase 1
Planned participants42
Who can joinAll sexes, 18 Years to no upper limit
Healthy volunteersNo

About this study

This phase 1, single-center, open-label study explores the safety of escalating doses of chimeric antigen receptor T cells (CAR-T) cells in subjects with relapsed/refractory triple-negative breast cancer (TNBC).

This description comes directly from the study's public registry record.

Talk to the study team

Caroline Babinec  ·  919-445-4208  ·  UNCImmunotherapy@med.unc.edu

Catherine Cheng  ·  +1 919-445-4208  ·  UNCImmunotherapy@med.unc.edu

Always discuss trial participation with your own doctor first.

Locations (1)

University of North CarolinaChapel Hill, North Carolina, United StatesRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT06347068